David Mitcheson

Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder

Christopher R. Chapple, Steven A. Kaplan, David Mitcheson et al. · European Urology · 2012 · 350 citations

Urological Research, Urology, Voiding Dysfunction +6

Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)

Marcus J. Drake, Christopher R. Chapple, Adil Esen et al. · European Urology · 2016 · 181 citations · Full text

Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder ( <scp>SYNERGY</scp> study)

Sender Herschorn, Christopher R. Chapple, Paul Abrams et al. · British Journal of Urology · 2017 · 171 citations · Full text

Urodynamics and Safety of the β ₃ -Adrenoceptor Agonist Mirabegron in Males with Lower Urinary Tract Symptoms and Bladder Outlet Obstruction

Victor W. Νitti, Steven Rosenberg, David Mitcheson et al. · The Journal of Urology · 2013 · 162 citations

Mirabegron 50 mg once‐daily for the treatment of symptoms of overactive bladder: An overview of efficacy and tolerability over 12 weeks and 1 year

Christopher R. Chapple, Steven A. Kaplan, David Mitcheson et al. · International Journal of Urology · 2014 · 45 citations · Full text